Absci Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Absci wird ein Gewinn- und Umsatzwachstum von 22.5% bzw. 46% pro Jahr prognostiziert, während der Gewinn pro Aktie um 27.3% pro Jahr wachsen soll.

Wichtige Informationen

22.5%

Wachstumsrate der Gewinne

27.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	46.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	24 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

Jan 10

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Jul 22

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ABSI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	43	-67	N/A	-47	4
12/31/2025	21	-83	N/A	-48	6
12/31/2024	7	-88	N/A	-61	5
3/31/2024	5	-109	-63	-62	N/A
12/31/2023	6	-111	-65	-65	N/A
9/30/2023	7	-106	-70	-68	N/A
6/30/2023	9	-112	-83	-77	N/A
3/31/2023	6	-99	-90	-80	N/A
12/31/2022	6	-105	-98	-81	N/A
9/30/2022	6	-111	-104	-80	N/A
6/30/2022	5	-107	-107	-83	N/A
3/31/2022	5	-121	-113	-74	N/A
12/31/2021	5	-103	-99	-61	N/A
9/30/2021	6	-84	-77	-46	N/A
6/30/2021	5	-73	-53	-27	N/A
3/31/2021	5	-48	-24	-16	N/A
12/31/2020	5	-49	-13	-11	N/A
12/31/2019	2	-24	-7	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ABSI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ABSI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ABSI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ABSIDie Einnahmen des Unternehmens (46% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ABSIDie Einnahmen des Unternehmens (46% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ABSI in 3 Jahren voraussichtlich hoch sein wird

Absci Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 26%

Consensus revenue estimates fall by 20%

Consensus revenue estimates decrease by 13%

Price target decreased by 14% to US$5.76

Consensus revenue estimates decrease by 42%

Price target decreased by 15% to US$5.50

Recent updates

Is Absci (NASDAQ:ABSI) A Risky Investment?

Chief Business Officer & CFO notifies of intention to sell stock

Chief Business Officer & CFO notifies of intention to sell stock

Consensus revenue estimates decrease by 26%

Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Absci Corporation to Report Q1, 2024 Results on May 14, 2024

Consensus revenue estimates fall by 20%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates decrease by 13%

New minor risk - Shareholder dilution

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci: Differentiated Antibody Discovery Play

Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and Optimized Using Generative Ai

Absci Corporation to Present Preclinical Data for ABS-101, A Potential Best-In-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024

Price target decreased by 14% to US$5.76

Consensus revenue estimates decrease by 42%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 15% to US$5.50

Consensus EPS estimates fall by 21%, revenue upgraded

Absci Corporation Announces Resignation of Sarah Korman as Chief Legal Officer and Interim Chief Business Officer, Effective as of September 15, 2023

Absci Corporation Appoints Zach Jonasson as Chief Business Officer, Effective from August 31, 2023

Absci Corporation Reports Impairment Results for the Second Quarter Ended June 30, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation and California Institute of Technology Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

New major risk - Share price stability

Absci Corporation Appoints Frans Van Houten to Its Board of Directors

Price target decreased by 10% to US$7.73

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Casdin Capital Engages in Discussions with Absci Corporation

Price target decreased by 28% to US$8.60

Consensus revenue estimates decrease by 23%, EPS upgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Casdin Capital Engages in Discussions with Absci Corporation

Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

Absci Corporation Announces Ability to Create and Validate de novo Antibodies in Silico with Use of Zero-Shot Generative AI

Consensus forecasts updated

Price target decreased to US$12.10

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation Appoints Dan Rabinovitsj as Newest Member of its Board of Directors

Chief Financial Officer exercised options to buy US$155k worth of stock.

Absci Corporation Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer

Absci Corporation Announces End of Nikhil Goel as Chief Strategy Officer

Price target decreased to US$13.10

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M

Eli Casdin Resigns from Board of Directors of Absci Corporation

Absci teams up to help develop antibody drugs for cancer

Absci Corporation(NasdaqGS:ABSI) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus EPS estimates fall by 29%

Consensus revenue estimates fall by 17%

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.33 loss per share

Absci, CORP has completed an IPO in the amount of $200 million.

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken